Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07759011
Starting soon Not applicable

Clinical Study of Spectral CT Verida

NCT07759011 · tracked via the Priya Life Science China tracker
Sponsor
Philips Clinical & Medical Affairs Global
Phase
Not applicable
Started
2026-07-30
Last updated
2026-08-11

Condition(s) studied

Volunteers

Investigational drug(s) / intervention(s)

CT Radiation Scan

CT Radiation Scan: Use investigated CT do radiation scan

Study summary

This study will prospective enroll 80 subjects to evaluate the comparison of image quality, proportion of high-quality images, and image noise between the Spectral Precise Image (SPI) intelligent denoising for low-dose scans on the Spectral CT Verida system and iDose4 reconstructions after low-dose and routine-dose scans.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria: * 18 ≤ age ≤ 75 years. * 18 kg/m² ≤ BMI ≤ 28 kg/m². * Conscious, able to cooperate, and competent to perform study procedures. Voluntarily agrees to participate in this clinical study and has signed the informed consent form. * Women of childbearing potential must have a negative pregnancy test and have no plans to become pregnant during the next 6 months. Exclusion Criteria: * Persons without full civil capacity. * Pregnant or breastfeeding women. * Any other conditions that, in the investigator's judgment, make the subject unsuitable for participation in this clinical study.

Primary outcome measure(s)

  • The rate of good-excellent scores ≥3 — From date of image reconstruction until the date of image reading completion, anticipated 1Week.
    Image quality will be assessed by 2 radiologists using Likert-scale on a range from 1(poor) to 5(Excellent),and calculate the rate of ≥3 with FAS,PSS SS as the datasets analysis.

Trial sites (1)

FacilityCityRegionStatus
No. 107 Wenhua West Road, Lixia District Jinan Shandong

More Philips Clinical & Medical Affairs Global trials in China

Spectral Precise Image Study for Brain Tumors Recruiting
Clinical Study of Spectral CT Starting soon
Spectral Precise Image Study for Coronary Artery Starting soon
Spectral Precise Image-Colon Cancer Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07759011 on ClinicalTrials.gov ↗ ← All trials in China